Neos Therapeutics Resubmits NDA for FDA Review of Amphetamine Extended-Release Orally Disintegrating Tablets to Treat ADHD

by Benzinga Staff
July 30, 2015 7:11 AM | 27 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Neos Therapeutics, Inc. (NASDAQ: NEOS today announced that it has resubmitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its amphetamine XR orally disintegrating tablet ("XR-ODT") product candidate, NT‐0202, for the treatment of ADHD. The NT-0202 NDA resubmission provides information to specifically address the FDA-issued Complete Response Letter received in September 2013. This includes the results from an additional pharmacokinetic study which was conducted with NT-0202 that utilized a commercial-scale manufacturing process, and the requisite stability data. This submission

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Posted In: NewsFDAPress Releases

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.